These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 15893119)

  • 1. RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen.
    Guha SK
    Med Hypotheses; 2005; 65(1):61-4. PubMed ID: 15893119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive.
    Guha SK
    Asian J Androl; 2007 Mar; 9(2):221-7. PubMed ID: 17334590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RISUG: a potential candidate for the entry inhibitor group of antiretroviral drugs.
    Banerjee S; Guha SK
    Med Hypotheses; 2009 Aug; 73(2):150-2. PubMed ID: 19409721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the membrane integrity of human sperm treated with a new injectable male contraceptive.
    Chaudhury K; Bhattacharyya AK; Guha SK
    Hum Reprod; 2004 Aug; 19(8):1826-30. PubMed ID: 15192063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topological alterations in human spermatozoa associated with the polyelectrolytic effect of RISUG.
    Kumar S; Chaudhury K; Sen P; Guha SK
    Micron; 2006; 37(6):526-32. PubMed ID: 16504524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the micro-structural properties of RISUG--a newly developed male contraceptive.
    Kumar S; Roy S; Chaudhury K; Sen P; Guha SK
    J Biomed Mater Res B Appl Biomater; 2008 Jul; 86(1):154-61. PubMed ID: 18161821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative suitability of DMSO and NaHCO3 for reversal of RISUG® induced long-term contraception.
    Ansari AS; Hussain M; Khan SR; Lohiya NK
    Andrology; 2016 Mar; 4(2):306-13. PubMed ID: 26748683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG.
    Chaki SP; Das HC; Misro MM
    Contraception; 2003 Jan; 67(1):73-8. PubMed ID: 12521662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A proton NMR study of the effect of a new intravasal injectable male contraceptive RISUG on seminal plasma metabolites.
    Sharma U; Chaudhury K; Jagannathan NR; Guha SK
    Reproduction; 2001 Sep; 122(3):431-6. PubMed ID: 11597307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charging the vas deferens -- a novel male contraceptive method.
    Koshy LM
    Indian Med Trib; 1994 Aug; 2(14):6. PubMed ID: 12179180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of an injectable contraceptive for the male.
    Guha SK; Singh G; Anand S; Ansari S; Kumar S; Koul V
    Contraception; 1993 Oct; 48(4):367-75. PubMed ID: 8222664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sperm characteristics and teratology in rats following vas deferens occlusion with RISUG and its reversal.
    Lohiya NK; Suthar R; Khandelwal A; Goyal S; Ansari AS; Manivannan B
    Int J Androl; 2010 Feb; 33(1):e198-206. PubMed ID: 19811546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience.
    Sharma RS; Mathur AK; Singh R; Das HC; Singh GJ; Toor DPS; Guha SK
    Indian J Med Res; 2019 Jul; 150(1):81-86. PubMed ID: 31571633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of a vas deferens injectable contraceptive for the male.
    Guha SK; Singh G; Ansari S; Kumar S; Srivastava A; Koul V; Das HC; Malhotra RL; Das SK
    Contraception; 1997 Oct; 56(4):245-50. PubMed ID: 9408706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a new injectable male contraceptive on the seminal plasma amino acids studied by proton NMR spectroscopy.
    Chaudhury K; Sharma U; Jagannathan NR; Guha SK
    Contraception; 2002 Sep; 66(3):199-204. PubMed ID: 12384210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraception with RISUG
    Ansari AS; Badar A; Balasubramanian K; Lohiya NK
    Asian J Androl; 2017; 19(4):389-395. PubMed ID: 27586026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical toxicity study of a male injectable antifertility agent (styrene maleic anhydride) in rhesus monkeys, Macaca mulatta.
    Sethi N; Srivastava RK; Nath D; Singh RK
    J Med Primatol; 1991; 20(2):89-93. PubMed ID: 1865485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyelectrolyte polymer properties in relation to male contraceptive RISUG action.
    Roy S; Ghosh D; Guha SK
    Colloids Surf B Biointerfaces; 2009 Feb; 69(1):77-84. PubMed ID: 19111447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of genotoxicity in leukocytes and testis following intra-vasal contraception with RISUG and its reversal by DMSO and NaHCO₃ in Wistar albino rats.
    Ansari AS; Alam I; Hussain M; Khan SR; Lohiya NK
    Reprod Toxicol; 2013 Apr; 36():53-9. PubMed ID: 23246611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive reversal of intraluminal vas deferens polymer injection-induced azoospermia--technology.
    Guha SK
    Asian J Androl; 1999 Sep; 1(3):131-4. PubMed ID: 11250780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.